Abstract
Background
COVID-19, a disease caused by infection with the SARS-CoV-2 virus, is asymptomatic or mildly symptomatic in most cases. Some patients, usually burdened with risk factors develop acute respiratory failure and other organ dysfunction. In such cases, the mortality rate is very high despite the use of intensive therapy. Amantadine has complex activity including antiviral, antiinflammatory and dopaminergic effects. This clinical trial will assess the efficacy and safety of amantadine in the prevention of COVID-19 progression toward acute respiratory failure and neurological complications.
Methods and results
The trial will enroll 200 patients who are positive for SARS-CoV-2 infection and have one or more risk factors for worsening the disease. These patients will be included as hospitalized or ambulatory subjects for early treatment of illness. The recruitment will take place in 8 centers covering different regions of Poland. For 14 days they will be given either 200 mg of amantadine a day or placebo. Our hypothesis is a considerable reduction in the number of patients with progression toward respiratory insufficiency or neurological complications thanks to the treatment of amantadine.
Conclusions
Demonstrating the efficacy and safety of amantadine treatment in improving the clinical condition of patients diagnosed with COVID-19 is of great importance in combating the effects of the pandemic. It has potential to influence on the severity and course of neurological complications, which are very common and persist long after the infection as long-COVID syndrome.
Clinical trial registration:www.clinicaltrials.gov identification no. NCT04854759; Eudra CT number: 2021–001144-98 (dated 27 February 2021).
【저자키워드】 COVID-19, protocol, Trial, outcome, amantadine, Neurological complications, 【초록키워드】 Treatment, clinical trial, pandemic, therapy, Hospitalized, Respiratory failure, Antiviral, SARS-COV-2 infection, severity, Infection, progression, Poland, risk factor, Region, Asymptomatic, symptomatic, clinical, early treatment, Patient, organ dysfunction, Efficacy and safety, long-COVID, Placebo, mortality rate, recruitment, disease, Intensive, patients, Hypothesis, Neurological complication, subject, complex, worsening, syndrome, clinical condition, positive, Effect, Effects, antiinflammatory, combating, prevention of COVID-19, Course, develop, caused, the disease, reduction in, Demonstrating, diagnosed with COVID-19, the SARS-CoV-2 virus, 【제목키워드】 Treatment, progression, Patient, COVID-19 symptom, the SARS-CoV-2 virus,